This result will open up new opportunities for pivotal preclinical single and repeat dose safety studies following good laboratory practices (GLP) as mandatory by regulatory agencies for investigational new drug (IND) applications (Kanakia et al. 2014).
The DSMD will perform ongoing review of safety and efficacy data to minimise exposure of patients to unsafe therapy or dose, make recommendations for changes in the study processes where appropriate, advise on the need for dose adjustment for safety issues and endorse study continuation.
Therefore, a rational approach for dose selection that considers both safety and efficacy should precede the standard PK study, especially for drugs with renal excretion and low therapeutic range.
Further details on reasons for dose reduction are provided in the Safety section.
The primary safety end-point for dose escalation was the incidence of grade 3 (severe) or 4 (life-threatening) adverse events (AEs).
Consideration should be given to using fixed dose guidelines independent of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may have accuracy, safety and financial advantages.
We found that the extended mTPI design selects the optimal dose for safety and efficacy more accurately than the other designs for most of the scenarios considered.
40 healthy adults aged 18 50 years test one of four combinations of intramuscular (IM) or intranasal (IN) PanAd3-RSV prime and IM PanAd3 or IM MVA-RSV boost vaccination, starting at a low dose for safety.
However, proper blinding would have been difficult because of the necessary reduction in insulin dose (for safety reasons) in liraglutide-treated patients and because of the gastrointestinal adverse effects.
Together, most of the clinical trials and meta-analysis which evaluated efficacy and safety for dose-dense paclitaxel suggested a trend of larger therapeutic window and a better safety efficacy profile for qw paclitaxel compared with q3w regimen and provided support for the Norton Simon hypothesis.
